These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Group I PAK inhibitor IPA-3 induces cell death and affects cell adhesivity to fibronectin in human hematopoietic cells. Kuželová K; Grebeňová D; Holoubek A; Röselová P; Obr A PLoS One; 2014; 9(3):e92560. PubMed ID: 24664099 [TBL] [Abstract][Full Text] [Related]
13. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers. Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375 [TBL] [Abstract][Full Text] [Related]
14. Secretory phospholipase A2 mediates human esophageal adenocarcinoma cell growth and proliferation via ERK 1/2 pathway. Sadaria MR; Yu JA; Meng X; Fullerton DA; Reece TB; Weyant MJ Anticancer Res; 2013 Apr; 33(4):1337-42. PubMed ID: 23564770 [TBL] [Abstract][Full Text] [Related]
15. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992 [TBL] [Abstract][Full Text] [Related]
16. β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation. Liu JS; Che XM; Chang S; Qiu GL; He SC; Fan L; Zhao W; Zhang ZL; Wang SF World J Gastroenterol; 2015 Sep; 21(34):9945-56. PubMed ID: 26379399 [TBL] [Abstract][Full Text] [Related]
17. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004 [TBL] [Abstract][Full Text] [Related]
19. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer. Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747 [TBL] [Abstract][Full Text] [Related]
20. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Jensen SS; Andresen TL; Davidsen J; Høyrup P; Shnyder SD; Bibby MC; Gill JH; Jørgensen K Mol Cancer Ther; 2004 Nov; 3(11):1451-8. PubMed ID: 15542784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]